Ionis Pharmaceuticals (IONS) Financial Analysis & Valuation | Quarter Chart
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis... more
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. T... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $7.13B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Brett Monia |
| IPO Date | 1991-05-17 | CAGR | 19.23% |
| Employees | 1,480 | Website | www.ionispharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
IONS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $12.78B | P/E | -13.13 | Forward P/E | -37.45 | PEG | — |
| P/S | 1.02 | P/B | 2.02 | P/CF | -1.78 | P/FCF | -1.58 |
| Sales | $873.76M | Sales 1Y | -7.45% | Sales 3Y | 38.56% | Sales 5Y | 27.05% |
| EPS | $-3.27 | EPS 1Y | 86.02% | EPS 3Y | 60.19% | EPS 5Y | -10.36% |
| Sales QoQ | 8.88% | EPS QoQ | 23.21% | Sales QoQ Avg | -1.42% | EPS QoQ Avg | -44.62% |
| Gross Margin | 98.16% | Operating Margin | -68.09% | Profit Margin | -64.64% | ROCE | -22.21% |
| ROA | -19% | ROE | -111% | Altman Z Score | 0.98 | Piotroski Score | 2 |
| Current Ratio | 7.89 | Quick Ratio | 7.73 | Cash Ratio | 1.11 | Op. CF Ratio | 1.79 |
| Debt/Equity | 3.67 | Debt/Assets | 0.54 | Lt Debt/Equity | 4.27 | Lt Debt/Cap. | 0.79 |
| Intrst Cov. | -9.48 | Inventory Turnover | 0.32 | Asset Turnover | 0.29 | Receivables Turnover | 14.85 |
| Enterprise Value | $12.78B | P/E Ratio | -13.13 |
| Forward P/E | -37.45 | PEG Ratio | — |
| P/S Ratio | 1.02 | P/B Ratio | 2.02 |
| P/CF Ratio | -1.78 | P/FCF Ratio | -1.58 |
| EPS | $-3.27 | EPS Growth 1Y | 86.02% |
| EPS Growth 3Y | 60.19% | EPS Growth 5Y | -10.36% |
| Revenue Growth 1Y | -7.45% | Gross Margin | 98.16% |
| Operating Margin | -68.09% | Profit Margin | -64.64% |
| ROE | -111% | ROA | -19% |
| ROCE | -22.21% | Current Ratio | 7.89 |
| Quick Ratio | 7.73 | Cash Ratio | 1.11 |
| Debt/Equity | 3.67 | Interest Coverage | -9.48 |
| Altman Z Score | 0.98 | Piotroski Score | 2 |
Ionis Pharmaceuticals (IONS) valuation & financials
Ionis Pharmaceuticals (IONS) has a market capitalization of $7.13B and trades at a price-to-earnings ratio of -13.1. It operates in the Healthcare sector (Biotechnology).
Ionis Pharmaceuticals's revenue grew -7.4% over the last year.
Ionis Pharmaceuticals's next earnings report is scheduled for November 4, 2026 (provider scheduled date); analysts estimate EPS of $-1.21. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)